Live price temporarily unavailable.
Werewolf Therapeutics (HOWL) is a Health Care company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$22.4M | −$50.1M | −$56.1M | −$40.5M | −$73.6M | −$60.7M |
| Net income | −$15.0M | −$50.0M | −$53.8M | −$37.4M | −$70.5M | −$60.8M |
| EPS (diluted) | −$28.08 | −$10.94 | −$1.86 | −$1.05 | −$1.63 | −$1.33 |
| Balance sheet | ||||||
| Cash and equivalents | $92.6M | $157.5M | $129.3M | $134.3M | $111.0M | $57.0M |
| Total assets | $96.4M | $179.3M | $160.2M | $174.8M | $126.9M | $69.4M |
| Total liabilities | $7.18M | $26.5M | $37.9M | $63.5M | $53.5M | $44.6M |
| Long-term debt | — | — | — | $40.0M | $32.1M | $32.1M |
| Shareholders' equity | −$51.9M | $152.8M | $122.3M | $111.4M | $73.4M | $24.8M |
| Cash flow | ||||||
| Operating cash flow | −$18.6M | −$42.9M | −$40.6M | −$32.6M | −$56.2M | −$60.3M |
| Capital expenditure | $560.0K | $498.0K | $3.61M | $769.0K | $254.0K | $0 |
| Free cash flow | −$19.2M | −$43.4M | −$44.2M | −$33.4M | −$56.4M | −$60.3M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$17.1M | −$20.3M | −$18.0M | −$17.5M | −$15.7M | −$9.42M | −$13.3M | $7.16M |
| Net income | −$16.7M | −$20.4M | −$18.1M | −$18.0M | −$16.4M | −$8.38M | −$13.5M | $3.67M |
| EPS (diluted) | −$0.38 | −$0.43 | −$0.40 | −$0.40 | −$0.36 | −$0.17 | −$0.28 | $0.08 |
| Balance sheet | ||||||||
| Cash and equivalents | $122.8M | $111.0M | $92.0M | $77.6M | $65.7M | $57.0M | $46.5M | $22.0M |
| Total assets | $140.0M | $126.9M | $107.2M | $92.6M | $79.6M | $69.4M | $58.0M | $24.2M |
| Total liabilities | $50.7M | $53.5M | $49.9M | $51.1M | $50.0M | $44.6M | $45.8M | $7.86M |
| Long-term debt | $32.1M | $32.1M | $32.1M | $32.1M | $32.1M | $32.1M | $32.1M | — |
| Shareholders' equity | $89.4M | $73.4M | $57.3M | $41.5M | $29.6M | $24.8M | $12.2M | $16.3M |
| Cash flow | ||||||||
| Operating cash flow | −$12.5M | −$14.3M | −$18.9M | −$15.2M | −$15.2M | −$11.0M | −$10.6M | $6.63M |
| Capital expenditure | $3.00K | $123.0K | $0 | $0 | $0 | $0 | — | — |
| Free cash flow | −$12.5M | −$14.4M | −$18.9M | −$15.2M | −$15.2M | −$11.0M | — | — |
From Werewolf Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Werewolf Therapeutics in our feed yet.